Deep Vein Thrombosis
📧 Sign up to get email alerts when something new happens for Deep Vein Thrombosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-12-12Clinical Trial Update: Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy [Phase 3]
A Phase 3 trial evaluated apixaban to prevent recurrent cancer-related venous thromboembolism in patients who completed initial anticoagulat…
-
CLINICAL_TRIALS trial_result · 2023-11-28Clinical Trial Update: OsciPulse Device for the Prevention of VTE [NA]
Completed clinical trial of the OsciPulse device for prevention of venous thromboembolism with results posted in 2023.
-
FDA approval · 2023-10-18FDA Approved: SAVAYSA — Supplemental Application (Daiichi Sankyo Inc.)
FDA approves a supplemental application for SAVAYSA (edoxaban tosylate) from Daiichi Sankyo, resulting in an update to the drug’s labeling.
-
CLINICAL_TRIALS trial_result · 2023-10-11Clinical Trial Update: Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study [Phase 1]
Phase 1 pediatric PK/PD study completed; results posted.
-
CLINICAL_TRIALS trial_result · 2023-10-03Clinical Trial Update: Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer [NA]
A completed clinical trial comparing direct oral anticoagulants (DOACs) to LMWH with or without warfarin for venous thromboembolism in cance…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-09-28Clinical Trial Update: Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis [Phase 4]
Phase 4 clinical trial update for apixaban in routine management of upper extremity deep venous thrombosis; study status terminated.
-
CLINICAL_TRIALS trial_result · 2023-09-07Clinical Trial Update: Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT) [Phase 2]
Phase 2 trial of BAY59-7939 (oral direct Factor Xa inhibitor) in acute symptomatic proximal deep vein thrombosis has completed.
-
CLINICAL_TRIALS trial_result · 2023-08-07Clinical Trial Update: Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19 [Phase 4]
Phase 4 trial comparing weight-adjusted versus fixed low-dose low molecular weight heparin for venous thromboembolism prevention in COVID-19…
-
CLINICAL_TRIALS trial_result · 2023-05-06Clinical Trial Update: Study Evaluation of Recombinant Hirudin in Prophylaxis of Post-Operative Deep Vein Thrombosis [Phase 4]
Clinical trial update on recombinant hirudin for prophylaxis of postoperative deep vein thrombosis (Phase 4).
-
CLINICAL_TRIALS trial_result · 2023-03-06Clinical Trial Update: Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE) [Phase 3]
A Phase 3 pediatric trial evaluating edoxaban for confirmed venous thromboembolism has completed and posted results.
-
FDA approval · 2022-11-15FDA Approved: ENOXAPARIN SODIUM — Supplemental Application (Amphastar Pharmaceuticals, Inc.)
FDA approves Amphastar Pharmaceuticals' supplemental application for enoxaparin sodium.
-
CLINICAL_TRIALS trial_result · 2022-09-08Clinical Trial Update: A Study of the Efficacy of Preventive Dosing of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolism (VTE) in Patients Undergoing Coronary Bypass Surgery Receiving Routine Mechanical Prophylaxis [NA]
Clinical trial evaluating preventive dosing of fondaparinux vs placebo for preventing venous thromboembolism in patients undergoing coronary…
-
FDA approval · 2022-08-23FDA Approved: WARFARIN SODIUM — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for Warfarin sodium submitted by Amneal Pharmaceuticals LLC.
-
FDA approval · 2022-07-28FDA Approved: ENOXAPARIN SODIUM — Supplemental Application (Gland Pharma Limited)
FDA approved a supplemental application for enoxaparin sodium from Gland Pharma Limited.
-
CLINICAL_TRIALS trial_result · 2022-07-26Clinical Trial Update: Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis. [Phase 3]
Phase 3 trial updating on the prevention of recurrent thrombosis with Xarelto compared to no treatment in patients with chronic portal vein …
-
FDA approval · 2022-06-14FDA Approved: ENOXAPARIN SODIUM — Original Application (BluePoint Laboratories)
The FDA approved BluePoint Laboratories' original ANDA for enoxaparin sodium, a low molecular weight heparin, expanding availability of its …
-
CLINICAL_TRIALS trial_result · 2022-05-25Clinical Trial Update: Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19 [Phase 3]
Phase 3 trial of enoxaparin for primary thromboprophylaxis in ambulatory COVID-19 patients was terminated.
-
FDA approval · 2022-02-15FDA Approved: HEPARIN SODIUM — Supplemental Application (Sandoz Inc.)
FDA approved a supplemental application for Heparin Sodium submitted by Sandoz Inc., indicating an additional regulatory action on this gene…
-
FDA approval · 2022-01-12FDA Approved: HEPARIN SODIUM — Supplemental Application (Sagent Pharmaceuticals)
FDA approved a supplemental application for Heparin Sodium from Sagent Pharmaceuticals, confirming regulatory status and updates related to …
-
CLINICAL_TRIALS trial_result · 2021-12-09Clinical Trial Update: Screening for Cancer in Patients With Unprovoked VTE [Phase 4]
Phase 4 trial update focused on screening for cancer in patients with unprovoked venous thromboembolism.
-
CLINICAL_TRIALS trial_result · 2021-10-15Clinical Trial Update: Mechanisms of Deep Vein Thrombosis (DVT) and Vein Wall Fibrosis [Phase 1, Phase 2]
Early-phase clinical trial update on mechanisms of deep vein thrombosis and vein wall fibrosis in conditions including post-thrombotic syndr…
-
CLINICAL_TRIALS trial_result · 2021-07-29Clinical Trial Update: The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis [Phase 3]
Phase 3 trial update for apixaban in treating calf vein thrombosis (a form of deep vein thrombosis).
-
CLINICAL_TRIALS trial_result · 2021-05-18Clinical Trial Update: Physical Activity in Children at Risk of Post-thrombotic Sequelae (PACT) [NA]
Clinical trial update for the PACT study assessing physical activity in children at risk of post-thrombotic sequelae, with completed status …
-
CLINICAL_TRIALS trial_result · 2021-03-19Clinical Trial Update: D-dimer to Establish Duration of Anticoagulation After Venous Thromboembolism [Phase 4]
Phase 4 clinical trial updating D-dimer guidance to establish duration of anticoagulation after venous thromboembolism has completed.
-
FDA approval · 2020-12-29FDA Approved: HEPARIN SODIUM — Original Application (BE Pharmaceuticals Inc.)
FDA approved the original ANDA for Heparin Sodium from BE Pharmaceuticals Inc., providing a generic version of heparin for anticoagulation.